Piper Sandler initiated coverage on shares of Beta Bionics (NASDAQ:BBNX - Free Report) in a report issued on Monday, Marketbeat.com reports. The firm issued an overweight rating and a $26.00 price objective on the stock.
Other analysts have also recently issued research reports about the stock. Leerink Partners initiated coverage on shares of Beta Bionics in a report on Monday. They set an "outperform" rating and a $28.00 target price on the stock. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a report on Thursday, February 20th. Robert W. Baird initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 target price for the company. Finally, LADENBURG THALM/SH SH initiated coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.83.
Read Our Latest Report on BBNX
Beta Bionics Trading Down 0.4 %
Shares of NASDAQ BBNX traded down $0.08 during midday trading on Monday, hitting $19.91. 389,619 shares of the company traded hands, compared to its average volume of 332,212. Beta Bionics has a 12-month low of $18.67 and a 12-month high of $24.50.
Insider Transactions at Beta Bionics
In related news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now owns 3,901,599 shares of the company's stock, valued at $66,327,183. This trade represents a 34.46 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mike Mensinger bought 33,350 shares of the firm's stock in a transaction on Friday, January 31st. The shares were bought at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now owns 59,019 shares in the company, valued at approximately $1,003,323. The trade was a 129.92 % increase in their position. The disclosure for this purchase can be found here.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Recommended Stories
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
